INPEFA

This brand name is authorized in United States

Active ingredients

The drug INPEFA contains one active pharmaceutical ingredient (API):

1 Sotagliflozin UNII 6B4ZBS263Y - SOTAGLIFLOZIN

Sotagliflozin is an inhibitor of SGLT2 and SGLT1. Inhibiting SGLT2 reduces renal reabsorption of glucose and sodium which may influence several physiological functions such as lowering both pre-and afterload of the heart and downregulating sympathetic activity. Inhibiting SGLT1 reduces intestinal absorption of glucose and sodium which likely contributes to diarrhea. The mechanism for sotagliflozin’s cardiovascular benefits has not been established. Read about Sotagliflozin

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
INPEFA Tablet	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
A10BK06		A Alimentary tract and metabolism → A10 Drugs used in diabetes → A10B Blood glucose lowering drugs, excl. insulins → A10BK Sodium-glucose co-transporter 2 (SGLT2) inhibitors
Discover more medicines within A10BK06

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: US	FDA, National Drug Code	Identifier(s): 70183-221, 70183-240, 70183-241